Bionomics Limited American Depository Shares - BNOX STOCK NEWS

Bionomics Limited has announced the completion of target enrollment in its Phase 2b ATTUNE clinical trial, which aims to evaluate the efficacy of BNC210 for treating Post-Traumatic Stress Disorder (PTSD). The trial, involving approximately 200 participants, is a randomized, double-blind, placebo-controlled study expected to yield topline results in Q3 2023. The ATTUNE study focuses on patients aged 18-75 with a current PTSD diagnosis, assessing various psychological metrics over 12 weeks. This milestone underscores Bionomics' ambition in developing treatments for serious CNS disorders, following promising outcomes from its previous Phase 2 PREVAIL study for Social Anxiety Disorder (SAD). CEO Spyros Papapetropoulos expressed optimism about the transformative potential of BNC210 in addressing significant neuropsychiatric conditions.

Bionomics Limited (NASDAQ: BNOX) announced data from its Phase 2 PREVAIL study evaluating BNC210 for Social Anxiety Disorder (SAD). The analysis showed both 225 mg and 675 mg doses of BNC210 significantly reduced anxiety during public speaking tasks compared to placebo (p=0.037). Despite not meeting its primary endpoint, the study's post-hoc analysis revealed therapeutic potential across all phases of the task. BNC210 exhibited a favorable safety profile, aligning with a fast-acting non-sedating anxiolytic. The company plans an End of Phase 2 meeting to discuss late-stage SAD program advancements in the second half of 2023.

Bionomics Limited (ASX: BNO, NASDAQ: BNOX) released its FY2023 half-year report for the period ending December 31, 2022. This period was highlighted by advancements in its drug development pipeline, including the completion of the Phase 2 PREVAIL Study for BNC210 aimed at treating Social Anxiety Disorder (SAD). Although the primary endpoint was not met, a positive safety profile was noted. Additionally, the firm is progressing with the ATTUNE study for PTSD and has ongoing collaborations with Merck to address cognitive impairment in Alzheimer's disease. Bionomics raised $5 million through a recent ADS offering, with a cash balance of approximately $30.7 million as of December 31, 2022.

Bionomics Limited (Nasdaq: BNOX) released its Appendix 4C – Quarterly Cashflow Report for the quarter ending December 31, 2022. Key highlights include the announcement of the PREVAIL study results for BNC210 in Social Anxiety Disorder, which did not meet its primary endpoint but showed favorable trends in secondary endpoints. The company reported a cash balance of $30.70 million at the end of the quarter, down from $31.43 million. Additionally, research and development expenses rose by 77.71% to $6.32 million. Bionomics appointed Spyridon Papapetropoulos as CEO, effective January 5, 2023, to lead the ongoing analysis of the PREVAIL data.

Bionomics Limited announced that its Phase 2 PREVAIL study evaluating BNC210 for treating Social Anxiety Disorder (SAD) did not meet its primary endpoint. Despite this, participants showed trends toward improvement across other endpoints compared to placebo. The safety and tolerability of BNC210 remained favorable, consistent with prior results. The company will continue data analysis to determine next steps, with sufficient cash reserves to support operations into mid-2024. BNC210's unique mechanism of action could still hold promise for future clinical development.

Bionomics Limited has appointed Spyridon "Spyros" Papapetropoulos, M.D. as its new President and CEO, effective January 5, 2023. This transition marks a pivotal moment for the company as it evolves from early-stage development to later-stage clinical and commercial operations. Papapetropoulos brings 25 years of experience in biopharmaceuticals with a focus on CNS disorders. He has held key roles in several notable companies, including Vigil Neuroscience and Acadia Pharmaceuticals. The company anticipates significant growth as it awaits results from ongoing clinical trials for its lead drug candidate, BNC210.